These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25259544)

  • 1. Exploiting the therapeutic potential of leptin signaling in cachexia.
    Mak RH; Cheung WW; Gertler A
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):352-7. PubMed ID: 25259544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice.
    Cheung WW; Ding W; Gunta SS; Gu Y; Tabakman R; Klapper LN; Gertler A; Mak RH
    J Am Soc Nephrol; 2014 Jan; 25(1):119-28. PubMed ID: 24115476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of Potent Leptin Receptor Antagonists and Their Therapeutic Use in Mouse Models of Uremic Cachexia and Kidney Fibrosis.
    Mak RH; Cheung WW; Solomon G; Gertler A
    Curr Pharm Des; 2018; 24(9):1012-1018. PubMed ID: 29366406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin and inflammation-associated cachexia in chronic kidney disease.
    Mak RH; Cheung W; Cone RD; Marks DL
    Kidney Int; 2006 Mar; 69(5):794-7. PubMed ID: 16518340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MC4 receptor antagonists: a potential treatment for cachexia.
    Foster AC; Chen C; Markison S; Marks DL
    IDrugs; 2005 Apr; 8(4):314-9. PubMed ID: 15800806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of melanocortin antagonists in cachexia of chronic disease.
    Scarlett JM; Marks DL
    Expert Opin Investig Drugs; 2005 Oct; 14(10):1233-9. PubMed ID: 16185165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease.
    DeBoer MD; Marks DL
    Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):459-66. PubMed ID: 16932335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cachexia: lessons from melanocortin antagonism.
    Deboer MD; Marks DL
    Trends Endocrinol Metab; 2006 Jul; 17(5):199-204. PubMed ID: 16750633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia.
    Foster AC; Chen C
    Curr Top Med Chem; 2007; 7(11):1131-6. PubMed ID: 17584133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on melanocortin interventions for cachexia: progress toward clinical application.
    DeBoer MD
    Nutrition; 2010 Feb; 26(2):146-51. PubMed ID: 20004082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease.
    Mak RH; Cheung W; Cone RD; Marks DL
    Pediatr Nephrol; 2005 Mar; 20(3):427-31. PubMed ID: 15662537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist.
    Markison S; Foster AC; Chen C; Brookhart GB; Hesse A; Hoare SR; Fleck BA; Brown BT; Marks DL
    Endocrinology; 2005 Jun; 146(6):2766-73. PubMed ID: 15774557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of leptin and melanocortin signaling in uremia-associated cachexia.
    Cheung W; Yu PX; Little BM; Cone RD; Marks DL; Mak RH
    J Clin Invest; 2005 Jun; 115(6):1659-65. PubMed ID: 15931394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremia-associated cachexia in mice.
    Cheung WW; Kuo HJ; Markison S; Chen C; Foster AC; Marks DL; Mak RH
    J Am Soc Nephrol; 2007 Sep; 18(9):2517-24. PubMed ID: 17687077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanocortin interventions in cachexia: how soon from bench to bedside?
    DeBoer MD
    Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):457-62. PubMed ID: 17563464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides.
    Ramos EJ; Suzuki S; Marks D; Inui A; Asakawa A; Meguid MM
    Curr Opin Clin Nutr Metab Care; 2004 Jul; 7(4):427-34. PubMed ID: 15192446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.
    Cheung WW; Mak RH
    Am J Physiol Renal Physiol; 2012 Nov; 303(9):F1315-24. PubMed ID: 22914778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer anorexia-cachexia syndrome: are neuropeptides the key?
    Inui A
    Cancer Res; 1999 Sep; 59(18):4493-501. PubMed ID: 10493494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia.
    Mak RH; Cheung W; Cone RD; Marks DL
    Nat Clin Pract Nephrol; 2006 Sep; 2(9):527-34. PubMed ID: 16941045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia.
    Zhu X; Callahan MF; Gruber KA; Szumowski M; Marks DL
    J Clin Invest; 2020 Sep; 130(9):4921-4934. PubMed ID: 32544087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.